Denali Therapeutics - 53 Year Dividend History | DNLI

Historical dividend payout and yield for Denali Therapeutics (DNLI) since 1971. The current TTM dividend payout for Denali Therapeutics (DNLI) as of May 21, 2024 is $0.00. The current dividend yield for Denali Therapeutics as of May 21, 2024 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.871B $0.331B
Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program partnered with Biogen to address Parkinson's disease, an eukaryotic translation initiation factor 2B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia (FTD), the ETV:IDS program, which utilizes the company's enzyme transport vehicle technology, and is designed to restore iduronate 2-sulfatase and reduce glycosaminoglycans, in patients with mucopolysaccharidosis II, and two separate receptor interacting serine/threonine protein kinase 1 inhibitor programs, both partnered with Sanofi. It also has a collaboration and option agreement with Takeda Pharmaceutical Co. Ltd. Takeda has exercised its option to jointly develop and commercialize DNL593 with the company.
Stock Name Country Market Cap PE Ratio